Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
Neurovine
Neurovine is a Series A stage prescription digital health platform that uses AI and connected wearables to improve brain recovery after a concussion. The proceeds will allow Neurovine to complete the second clinical trial and the regulatory process and to launch the product with Canadian physiotherapists and sports medicine physicians who have established billing codes.
Hear more from this company during the Early Technology Showcase.
Presenter: Ashleigh Kennedy, Founder
Read More
Notogen
Notogen is a preclinical-stage biotechnology company developing a novel regenerative biologic therapy for degenerative disc disease (i.e. chronic back and neck pain caused by degenerating spinal discs), a disease indication with no disease modifying treatments that is the largest unmet need in orthopedics and one of the largest unmet needs in healthcare. Notogen has had a successful pre-IND meeting with the FDA, has published impressive large animal in vivo data, has raised funding to complete its cGMP manufacturing and its IND-filing, and is now looking to raise a Series A round to finance its Phase I/IIa clinical trial and beyond.
Presenter: Gary Margolis, CEO
Read More
Nuro
NURO is an award-winning start-up from Waterloo, Ontario, which has developed NUOS, the Neural Operating System. With NUOS, incapacitated individuals in various states of Akinetic Mutism (due to Stroke, Trauma or Neurodegeneration) can now communicate and compute using brain signals. NUOS works instantly and without any surgery. NUOS is Health Canada cleared, US IRB cleared and US FDA cleared as the only non-invasive treatment of its kind. NUOS has been released in 3 editions after 6 years of R&D, 5 accelerators in Canada and Silicon Valley and over $1M of funding by SOSV / INDIE BIO, top medical doctors, The Ontario Centres of Excellence and other parties including Canada's FedDev, NRC-IRAP, MaRs, Mitacs, MIT, Google and more.
Presenter: Francois Gand, Founder and CEO
Read More
Perceiv
Perceiv is an AI-based digital biomarkers company specializing in the field of precision medicine. We are dedicated to reducing risks for patients and making clinical trials more cost-effective through advanced machine learning algorithms. We have secured $360K (USD) in non-dilutive public funding and we are seeking $2M (USD) in dilutive investment. These proceeds would go into making key hires (scientists, developers, and business development staff), operationalizing and commercializing our Alzheimer’s solution (product launch), supporting partnerships for data access with pharmaceutical companies and hospitals, and further improving our platform to accelerate new product development, and support the development new products (cardiovascular diseases).
Presenter: Christian Dansereau, CEO
Read More
PROTXX
PROTXX enhances care, outcomes, and healthcare economics for patients living with neuro-disruptive (e.g. concussion, stroke) and neuro-degenerative (e.g. multiple sclerosis, Parkinson’s disease) medical conditions. Our precision health platform integrates innovations in non-invasive wearable physiological sensors and machine learning classification of neurosensory and neuromotor impairments, replacing complex clinical equipment and time-consuming tests with easier-to-use, lower-cost, in-clinic and remote precision patient assessments. At the core of the PROTXX platform is the company’s “phybrata” sensor, a tiny, non-invasive device worn behind the ear that is able to classify, quantify, and monitor impairments to the major neurophysiological systems in the body.
Presenter: John Ralston, CEO and Founder
Read More
Spiderwort
Spiderwort is an innovative pre-clinical stage tissue engineering company specializing in the development of cellulose-based biomaterials with a lead indication in Spinal Cord Injury repair with the ultimate goal to improve human quality of life. The FDA has granted a Breakthrough Device Designation for Spiderwort’s spinal cord technology. Spiderwort is raising Series A capital to support clinical pilot studies.
Presenter: Charles Cuerrier, CEO
Read More
Steadiwear
Steadiwear develops battery-free gloves that stabilizes hand tremors in Parkinson’s disease & Essential tremor using technology was inspired by leading-edge earthquake dampers used in buildings. We are raising seed funding for clinical trial & health economics studies, manufacturing, and sales and marketing.
Presenter: Mark Elias, CEO
Read More
Synergy Disc Replacement
SDRi is a Canadian spinal medical device company pioneering a revolutionary artificial disc replacement implant technology - the only artificial disc implant that can both preserve motion and restore alignment to the spine. With a CE mark, Synergy has begun early commercialization efforts in last couple years in Europe and Australia. We have completed more than 1000 implants of the Synergy Disc with no device related adverse events. Synergy is now raising $15M USD to complete its FDA IDE clinical trial in pursuit of USA market approval, the largest market in the world for cervical artificial disc implants.
Presenter: Josh Butters, CEO
Read More
